New Insights into Antithrombotic Therapy for Cardio- and Cerebrovascular Disease: From Molecular Mechanisms to Clinical Application
Thrombosis is a pathophysiological phenomenon observed in acute and chronic coronary syndrome, stroke, and peripheral artery disease. Exposure of the Tissue Factor (TF) to flowing blood is followed to its binding to other coagulation factors leading to thrombin formation. Together with platelet acti...
Αποθηκεύτηκε σε:
| Μορφή: | Online |
|---|---|
| Γλώσσα: | Αγγλικά |
| Έκδοση: |
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Θέματα: | |
| Διαθέσιμο Online: | ONIX_20230808_9783036581163_28 |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|
| _version_ | 1869515011948281856 |
|---|---|
| collection | Directory of Open Access Books |
| description | Thrombosis is a pathophysiological phenomenon observed in acute and chronic coronary syndrome, stroke, and peripheral artery disease. Exposure of the Tissue Factor (TF) to flowing blood is followed to its binding to other coagulation factors leading to thrombin formation. Together with platelet activation, TF ultimately promotes thrombus formation. Recent advances in platelet pathophysiology have shown that these cells are able to regulate their gene/protein expression, engage in de novo protein synthesis, and release different mediators that may interfere with different cell functions. Several clinical trials have clearly shown the efficacy of anticoagulation and/or anti-platelet aggregation in different thrombotic disorders. Real-world practice clearly indicates that antithrombotic strategies need to be personalized according to patient characteristics. The combination of multiple antithrombotic drugs represents a challenging scenario and was the focus of multiple recent randomized controlled trials, with more still to come. As knowledge about platelets and the coagulation system has substantially evolved within the last few years, so should our approach to antithrombotic treatment; focused on current hurdles of antithrombotic treatments in patients with cardio- and cerebrovascular diseases, starting from the molecular mechanisms involved, proposing practical solutions to compelling clinical scenarios using a pathophysiology-oriented approach on the basis of current clinical evidence. |
| format | Online |
| id | doab-20.500.12854ir-112460 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1124602024-03-31T13:10:33Z New Insights into Antithrombotic Therapy for Cardio- and Cerebrovascular Disease: From Molecular Mechanisms to Clinical Application Cimmino, Giovanni Cirillo, Plinio P2Y12 inhibitor monotherapy percutaneous coronary intervention dual antiplatelet therapy high bleeding risk high on-treatment platelet reactivity randomized controlled trial left atrial appendage thrombus atrial fibrillation stroke oral anticoagulant cardiovascular diseases novel antithrombotic agents antiplatelet drugs anticoagulants hemostasis factor XI factor XI inhibitor thrombosis new drugs left ventricular thrombus anticoagulation anterior wall myocardial infarction dual therapy direct oral anticoagulants surface plasmon resonance metformin matrix metalloproteinase-9 plaque instability atherosclerosis cancer acute coronary syndrome (ACS) percutaneous coronary intervention (PCI) dual antiplatelet therapy (DAPT) triple antithrombotic therapy (TAT) atrial fibrillation (AF) cardiotoxicity aspirin coronary artery disease cerebrovascular disease diabetes mellitus essential thrombocythemia platelet function thromboxane gastrointestinal bleeding enteric-coated aspirin cardiovascular prevention P2Y12 inhibitors acute coronary syndrome clopidogrel prasugrel ticagrelor cangrelor selatogrel zalunfiban peripheral artery disease (PAD) antithrombotic therapy dual pathway inhibition (DPI) major adverse cardiovascular events (MACE) major adverse limb events (MALE) n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine Thrombosis is a pathophysiological phenomenon observed in acute and chronic coronary syndrome, stroke, and peripheral artery disease. Exposure of the Tissue Factor (TF) to flowing blood is followed to its binding to other coagulation factors leading to thrombin formation. Together with platelet activation, TF ultimately promotes thrombus formation. Recent advances in platelet pathophysiology have shown that these cells are able to regulate their gene/protein expression, engage in de novo protein synthesis, and release different mediators that may interfere with different cell functions. Several clinical trials have clearly shown the efficacy of anticoagulation and/or anti-platelet aggregation in different thrombotic disorders. Real-world practice clearly indicates that antithrombotic strategies need to be personalized according to patient characteristics. The combination of multiple antithrombotic drugs represents a challenging scenario and was the focus of multiple recent randomized controlled trials, with more still to come. As knowledge about platelets and the coagulation system has substantially evolved within the last few years, so should our approach to antithrombotic treatment; focused on current hurdles of antithrombotic treatments in patients with cardio- and cerebrovascular diseases, starting from the molecular mechanisms involved, proposing practical solutions to compelling clinical scenarios using a pathophysiology-oriented approach on the basis of current clinical evidence. 2023-08-08T15:12:57Z 2023-08-08T15:12:57Z 2023 book ONIX_20230808_9783036581163_28 9783036581163 9783036581170 https://directory.doabooks.org/handle/20.500.12854/112460 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/7573 https://mdpi.com/books/pdfview/book/7573 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-8117-0 10.3390/books978-3-0365-8117-0 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036581163 9783036581170 188 Basel open access |
| spellingShingle | P2Y12 inhibitor monotherapy percutaneous coronary intervention dual antiplatelet therapy high bleeding risk high on-treatment platelet reactivity randomized controlled trial left atrial appendage thrombus atrial fibrillation stroke oral anticoagulant cardiovascular diseases novel antithrombotic agents antiplatelet drugs anticoagulants hemostasis factor XI factor XI inhibitor thrombosis new drugs left ventricular thrombus anticoagulation anterior wall myocardial infarction dual therapy direct oral anticoagulants surface plasmon resonance metformin matrix metalloproteinase-9 plaque instability atherosclerosis cancer acute coronary syndrome (ACS) percutaneous coronary intervention (PCI) dual antiplatelet therapy (DAPT) triple antithrombotic therapy (TAT) atrial fibrillation (AF) cardiotoxicity aspirin coronary artery disease cerebrovascular disease diabetes mellitus essential thrombocythemia platelet function thromboxane gastrointestinal bleeding enteric-coated aspirin cardiovascular prevention P2Y12 inhibitors acute coronary syndrome clopidogrel prasugrel ticagrelor cangrelor selatogrel zalunfiban peripheral artery disease (PAD) antithrombotic therapy dual pathway inhibition (DPI) major adverse cardiovascular events (MACE) major adverse limb events (MALE) n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine New Insights into Antithrombotic Therapy for Cardio- and Cerebrovascular Disease: From Molecular Mechanisms to Clinical Application |
| title | New Insights into Antithrombotic Therapy for Cardio- and Cerebrovascular Disease: From Molecular Mechanisms to Clinical Application |
| title_full | New Insights into Antithrombotic Therapy for Cardio- and Cerebrovascular Disease: From Molecular Mechanisms to Clinical Application |
| title_fullStr | New Insights into Antithrombotic Therapy for Cardio- and Cerebrovascular Disease: From Molecular Mechanisms to Clinical Application |
| title_full_unstemmed | New Insights into Antithrombotic Therapy for Cardio- and Cerebrovascular Disease: From Molecular Mechanisms to Clinical Application |
| title_short | New Insights into Antithrombotic Therapy for Cardio- and Cerebrovascular Disease: From Molecular Mechanisms to Clinical Application |
| title_sort | new insights into antithrombotic therapy for cardio and cerebrovascular disease from molecular mechanisms to clinical application |
| topic | P2Y12 inhibitor monotherapy percutaneous coronary intervention dual antiplatelet therapy high bleeding risk high on-treatment platelet reactivity randomized controlled trial left atrial appendage thrombus atrial fibrillation stroke oral anticoagulant cardiovascular diseases novel antithrombotic agents antiplatelet drugs anticoagulants hemostasis factor XI factor XI inhibitor thrombosis new drugs left ventricular thrombus anticoagulation anterior wall myocardial infarction dual therapy direct oral anticoagulants surface plasmon resonance metformin matrix metalloproteinase-9 plaque instability atherosclerosis cancer acute coronary syndrome (ACS) percutaneous coronary intervention (PCI) dual antiplatelet therapy (DAPT) triple antithrombotic therapy (TAT) atrial fibrillation (AF) cardiotoxicity aspirin coronary artery disease cerebrovascular disease diabetes mellitus essential thrombocythemia platelet function thromboxane gastrointestinal bleeding enteric-coated aspirin cardiovascular prevention P2Y12 inhibitors acute coronary syndrome clopidogrel prasugrel ticagrelor cangrelor selatogrel zalunfiban peripheral artery disease (PAD) antithrombotic therapy dual pathway inhibition (DPI) major adverse cardiovascular events (MACE) major adverse limb events (MALE) n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine |
| topic_facet | P2Y12 inhibitor monotherapy percutaneous coronary intervention dual antiplatelet therapy high bleeding risk high on-treatment platelet reactivity randomized controlled trial left atrial appendage thrombus atrial fibrillation stroke oral anticoagulant cardiovascular diseases novel antithrombotic agents antiplatelet drugs anticoagulants hemostasis factor XI factor XI inhibitor thrombosis new drugs left ventricular thrombus anticoagulation anterior wall myocardial infarction dual therapy direct oral anticoagulants surface plasmon resonance metformin matrix metalloproteinase-9 plaque instability atherosclerosis cancer acute coronary syndrome (ACS) percutaneous coronary intervention (PCI) dual antiplatelet therapy (DAPT) triple antithrombotic therapy (TAT) atrial fibrillation (AF) cardiotoxicity aspirin coronary artery disease cerebrovascular disease diabetes mellitus essential thrombocythemia platelet function thromboxane gastrointestinal bleeding enteric-coated aspirin cardiovascular prevention P2Y12 inhibitors acute coronary syndrome clopidogrel prasugrel ticagrelor cangrelor selatogrel zalunfiban peripheral artery disease (PAD) antithrombotic therapy dual pathway inhibition (DPI) major adverse cardiovascular events (MACE) major adverse limb events (MALE) n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine |
| url | ONIX_20230808_9783036581163_28 |